mardi 24 juillet 2018

Onco Actu du 24 juillet 2018

1. Biologie

Breast cancer fuelled by mysterious Yin Yang protein [Imperial College London]

Experimental breast cancer drug could help patients with leukemia, too [FierceBiotech]

Rarity of cancer in elephants may help explain cancer in humans [Washington Post]

‘Hijacked’ Cell Response to Stress Reveals Promising Drug Targets for Blood Cancer [NYU Langone Health]

1.1 Biologie - Gènes

Analysis of prostate tumors reveals clues to cancer’s aggressiveness [WUSTL]

Massive genome havoc in breast cancer is revealed [Cold Spring Harbor Lab]

2.6 Etiologie - Environnement

Monsanto's 'cancer-causing' weedkiller destroyed my life, dying man tells court [The Guardian]

4. Dépistage, diagnostic et pronostic

Crunching Numbers: What Cancer Screening Statistics Really Tell Us [NCI]

4.2 Dép., diag. & prono. - Génome

What do people know about genome sequencing and medicine? [Enseqlopedia]

5.12.1 Immunothérapies - partenariats

Gritstone, Bristol-Myers Squibb to trial immunotherapy combos in solid tumors [FierceBiotech]

Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors [Gilead]

5.12.3 Immunothérapies-combinaisons

Roche's Tecentriq extends its hot streak with liver cancer combo breakthrough [FiercePharma]

5.12.5 Immunothérapies - Pharma

Bristol-Myers Squibb commercial chief Gordon jumps ship ahead of key Opdivo launch [FiercePharma]

5.2 Pharma

Lilly Oncology’s strategy? Listen to tough talk from patients—and save data for later [FiercePharma]

With FDA nod, Pfizer and Astellas’ Xtandi gets its shot at blockbuster sales boost [FiercePharma]

Celgene Announces Phase III ‘AUGMENT' Study of REVLIMID® in Combination with Rituximab (R²) for the Treatment of Patients with Relapsed/Refractory Indolent Lymphoma Met Primary Endpoint [Celgene]

5.2.1 Pharma - Partenariats

Immunomedics announces clinical collaboration with AstraZeneca in first-line triple-negative breast and urothelial cancers [Immunomedics]

Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial) [Puma]

5.3.4 Traitements - AMM (FDA, EMA,...)

FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation [Agios]

Agios wins FDA nod for targeted AML drug Tibsovo [FiercePharma]

Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women [Novartis]

FDA Approves Ivosidenib for Relapsed or Refractory Acute Myeloid Leukaemia [ESMO]

6.4 Médico-éco

2019 Medicare Reimbursement Proposed Cuts a Bad Idea for Individuals with Cancer [ASCO]

Doctors don't always recognize ‘financial toxicity’ of cancer [Reuters]

6.5 Médecines alternatives

Alternative Cancer Treatments May Be Bad for Your Health [NY Times]

6.6 Publications

Why Hasn’t the Academy Taken Back Control of Publishing Already? [The Scholarly Kitchen]

6.7.2 Applis

Novartis community-focused NET app gets a 'featured' boost from Apple's App Store [FiercePharma]